Sugi Predict

Sugi Predict / Compounds / SCHEMBL7802196

SCHEMBL7802196

SCHEMBL7802196

COC(=O)[C@@H]1CN1C(=O)OCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.52
▸ FKBP1A P62942 1/20 0.51
▸ PREP P48147 2/20 0.50
▸ NPC1 O15118 2/20 0.50
▸ RAB9A P51151 2/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ HTR2C P28335 1/20 0.50
▸ HTT P42858 2/20 0.49
▸ MITF O75030 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ PSEN1 P49768 1/20 0.48
▸ PSEN2 P49810 1/20 0.48
▸ APH1B Q8WW43 1/20 0.48
▸ NCSTN Q92542 1/20 0.48
▸ APH1A Q96BI3 1/20 0.48
▸ PSENEN Q9NZ42 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.47
▸ TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1864842 1.00 POLB (0.52) POLBFKBP1APREPNPC1RAB9A
SCHEMBL2300448 1.00 POLB (0.52) POLBFKBP1APREPNPC1RAB9A
SCHEMBL8525578 0.88 POLB (0.50) POLBFKBP1APREPNPC1RAB9A
SCHEMBL8487526 0.88 SMN1; SMN2 (0.54) FKBP1APREPNPC1RAB9ASMN1; SMN2
SCHEMBL15958489 0.88 POLB (0.53) POLBFKBP1APREPNPC1RAB9A
SCHEMBL7819386 0.88 POLB (0.50) POLBFKBP1APREPNPC1RAB9A
SCHEMBL4808093 0.88 POLB (0.50) POLBFKBP1APREPNPC1RAB9A
SCHEMBL4251706 0.88 POLB (0.64) POLBFKBP1APREPNPC1RAB9A
SCHEMBL636506 0.88 POLB (0.64) POLBFKBP1APREPNPC1RAB9A
SCHEMBL8482453 0.88 POLB (0.50) POLBFKBP1APREPNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3710458-B1 IMMUNOPROTEASOME INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2026-03-25 — — EP disclosed
EP-3681875-B1 CYCLIC PEPTIDE ANTIBIOTICS HOFFMANN LA ROCHE (CH) 2026-01-14 — — EP disclosed
US-20250388601-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2025-12-25 — — US disclosed
US-12358928-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2025-07-15 — — US disclosed
US-12312370-B2 Immunoproteasome inhibitors PRINCIPIA BIOPHARMA INC. (US) 2025-05-27 — — US disclosed
US-20250122212-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LIMITED (GB) 2025-04-17 — — US disclosed
EP-4486737-A1 SMALL MOLECULE MODULATORS OF IL-17 LEO Pharma A/S (DK) 2025-01-08 — — EP disclosed
CN-118994191-A Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2024-11-22 — — CN disclosed
CN-118994190-A Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2024-11-22 — — CN disclosed
CN-114437105-B Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2024-10-11 — — CN disclosed
WO-2012006055-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-01-12 — — WO disclosed
US-20100009957-A1 NOVEL INHIBITORS OF BETA-LACTAMASE MERCK SHARP & DOHME CORP. 2010-01-14 — — US disclosed
US-7632840-B2 Quinazoline compounds for the treatment of hyperproliferative disorders ASTRAZENECA AB (SE) 2009-12-15 — — US disclosed
US-7632840-B2 Quinazoline compounds for the treatment of hyperproliferative disorders ASTRAZENECA AB (SE) 2009-12-15 — — US disclosed
WO-2008039420-A2 NOVEL INHIBITORS OF BETA-LACTAMASE MERCK & CO., INC. (US) 2008-04-03 — — WO disclosed
US-20070293490-A1 Quinazoline Derivatives ASTRAZENECA AB (SE) 2007-12-20 — — US disclosed
US-20070293490-A1 Quinazoline Derivatives ASTRAZENECA AB (SE) 2007-12-20 — — US disclosed
EP-0855397-B1 (R)-5-BROMO-N-(1-ETHYL-4-METHYLHEXAHYDRO-1H-1,4-DIAZEPIN-6-YL)-2-METHOXY-6-METHYLAMINO-3-PYRIDINE-CARBOXAMIDE, PROCESS FOR PRODUCING THE SAME AND MEDICINAL COMPOSITION CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO (JP) 2001-05-09 — — EP disclosed
US-5945415-A GASTROINTESTINAL DISORDERS DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1999-08-31 — — US disclosed
EP-0855397-A1 (R)-5-BROMO-N-(1-ETHYL-4-METHYLHEXAHYDRO-1H-1,4-DIAZEPIN-6-YL)-2-METHOXY-6-METHYLAMINO-3-PYRIDINE-CARBOXAMIDE, PROCESS FOR PRODUCING THE SAME AND MEDICINAL COMPOSITION CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1998-07-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009957-A1 NOVEL INHIBITORS OF BETA-LACTAMASE MGAM, SI, MGAM2 POLB 823/4885FKBP1A 2407/4885PREP 77/4885
US-20250388601-A1 Compounds, Compositions and Methods AURKC, WEE2, ERBB2 POLB 700/4885FKBP1A 3445/4885PREP 4495/4885
US-12312370-B2 Immunoproteasome inhibitors PSMC2, PSMB7, PSMB2 POLB 692/4885FKBP1A 594/4885PREP 80/4885
US-20070293490-A1 Quinazoline Derivatives CCNA1, CCND3, CCND2 POLB 717/4885FKBP1A 2552/4885PREP 1500/4885
US-12358928-B2 Compounds, compositions and methods PIK3CA, PLK1, PIK3CB POLB 623/4885FKBP1A 3407/4885PREP 4769/4885
US-20250122212-A1 NOVEL COMPOUNDS CYP11B1, CYP11B2, UGT1A1 POLB 4170/4885FKBP1A 730/4885PREP 4112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.